LAUSR

ASA: aspirin IVIG: intravenous immune globulin KD: Kawasaki disease INTRODUCTION Kawasaki disease (KD), also known as mucocutaneous lymph node syndrome, is a systemic inflammatory illness thatmost commonly occurs in children. Its classic symptoms include fever, polymorphous eruption, oral mucosal changes, erythema and swelling of the hands and feet with eventual desquamation, lymphadenopathy, and conjunctivitis. Cardiac sequelae, mainly coronary artery aneurysms or ectasias, occur in up to 25% of untreated patients with KD. The cutaneous eruption has variable morphology including polymorphous, morbilliform, scarlatiniform, and may rarely present with a psoriasiform morphology. Approximately only 1.3% of patients with KDwill develop a psoriasiform pattern. This psoriasiform eruption may develop during or after the acute phase of the disease. Treatments for KD involve aspirin (ASA) and intravenous immune globulin (IVIG) as first-line therapies. For treatmentrefractory cases, immunomodulatory treatments, including corticosteroids, infliximab, anakinra, methotrexate, and cyclosporine, have been used. Cyclosporine may be beneficial for the treatment of recalcitrant KD, as recent evidence has demonstrated that the calcium-nuclear factor pathway may play a role in KDpathogenesis. However, there areminimal data regarding the treatment of the associated psoriasiform eruption when traditional therapies are ineffective. We present a case of refractory KD with psoriasiform eruption in a 5-month-old infant treated with cyclosporine.